Analystreport

Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.

Y-mAbs Therapeutics, Inc.  (YMAB) 
Last y-mabs therapeutics, inc. earnings: 11/13 04:01 pm Check Earnings Report